KPL Kwality Pharmaceuticals Q1 FY27 results (Apr–Jun 2026) and concall
Kwality Pharmaceuticals Limited reported Q1 FY27 with a gross margin of 53% and INR30-35 crores from oncology. The company provided extensive future guidance, targeting over INR700 crores revenue and 26-27% EBITDA margins for FY27, with a long-term goal of INR1,500 crores by 2030. Strategic capex of INR185-190 crores is planned for hormone, oncology, and biosimilar R&D, despite some delays in oncology and Erythropoietin registrations.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q1 FY27: revenue up 45.9%, net profit up 116.7% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 90 | 84 | 116 | 111 | 111 +23% | 123 +46% | 157 +35% | 162 +46% |
| EBITDA | 20 | 18 | 26 | 24 | 25 +25% | 30 +67% | 39 +50% | 41 +71% |
| Net profit | 8 | 9 | 14 | 12 | 14 +75% | 16 +78% | 25 +79% | 26 +117% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
